Gain Therapeutics (GANX) Net Income towards Common Stockholders (2020 - 2025)
Historic Net Income towards Common Stockholders for Gain Therapeutics (GANX) over the last 6 years, with Q3 2025 value amounting to -$5.3 million.
- Gain Therapeutics' Net Income towards Common Stockholders fell 1780.49% to -$5.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$21.9 million, marking a year-over-year decrease of 115.4%. This contributed to the annual value of -$22.9 million for FY2024, which is 163.48% down from last year.
- As of Q3 2025, Gain Therapeutics' Net Income towards Common Stockholders stood at -$5.3 million, which was down 1780.49% from -$5.8 million recorded in Q2 2025.
- Over the past 5 years, Gain Therapeutics' Net Income towards Common Stockholders peaked at -$2.5 million during Q1 2021, and registered a low of -$8.1 million during Q2 2024.
- Over the past 5 years, Gain Therapeutics' median Net Income towards Common Stockholders value was -$4.7 million (recorded in 2022), while the average stood at -$4.9 million.
- Per our database at Business Quant, Gain Therapeutics' Net Income towards Common Stockholders crashed by 55457.15% in 2021 and then soared by 2866.23% in 2025.
- Gain Therapeutics' Net Income towards Common Stockholders (Quarter) stood at -$3.2 million in 2021, then crashed by 45.17% to -$4.7 million in 2022, then fell by 7.25% to -$5.0 million in 2023, then decreased by 25.32% to -$6.3 million in 2024, then increased by 15.89% to -$5.3 million in 2025.
- Its Net Income towards Common Stockholders stands at -$5.3 million for Q3 2025, versus -$5.8 million for Q2 2025 and -$4.5 million for Q1 2025.